Emerging targeted therapies for plaque psoriasis – impact of ixekizumab

BACKGROUND: Recent studies into the pathogenesis of psoriasis have identified the importance of interleukin 17 (IL-17) in disease activity and have thus provided a new target for biologic therapy. Ixekizumab, the most recent US Food and Drug Administration (FDA)-approved anti-IL-17 biologic agent, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazemi, Tiana, Farahnik, Benjamin, Koo, John, Beroukhim, Kourosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409192/
https://www.ncbi.nlm.nih.gov/pubmed/28461763
http://dx.doi.org/10.2147/CCID.S111007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409192/
https://www.ncbi.nlm.nih.gov/pubmed/28461763
http://dx.doi.org/10.2147/CCID.S111007

Ejemplares similares